Corindus Vascular Robotics Inc. said Japan's Pharmaceutical and Medical Device Agency approved its robotic-assisted surgery platform.
The regulator approved the CorPath GRX system, a platform used in heart surgeries. Corindus said it is seeking reimbursement for CorPath GRX through the Japanese insurance system.
There is strong demand for robotic-assisted intervention in Japan, said President and CEO Mark Toland. About 250,000 percutaneous coronary interventions — a nonsurgical procedure for narrowing of the heart's arteries — are performed in Japan every year, making it one of the largest markets in the world for such procedures, the company said.
Japan Medicalnext Co. Ltd., a Mitsubishi Corp. unit, will distribute the platform in Japan.
The U.S. Food and Drug Administration previously approved Waltham, Mass.-based Corindus' CorPath GRX.
